Sun Li, Yu Da-hai, Sun San-Yuan, Zhuo Shi-Chao, Cao Su-sheng, Wei Ling
Department of Medical Oncology, The Central Hospital of Xuzhou, The Cancer Institute of Southeast University, Xuzhou, 221009, Jiangsu, China.
Cell Biochem Biophys. 2014 Apr;68(3):511-6. doi: 10.1007/s12013-013-9729-y.
In the present study, we evaluated expressions of estrogen receptor (ER), progestin receptor (PR), human epidermal growth factor receptor-2 (HER-2), cyclooxygenase-2 (COX-2), and vascular endothelial growth factor (VEGF) in primary and relapsed/metastatic breast cancers to elucidate the clinical significance of these markers. The markers were evaluated by immunohistochemistry in specimens of 50 patients with primary or metastatic breast cancer. Positive rates of ER were significantly (p = 0.002) higher in primary versus relapsed/metastatic breast cancer (70 vs. 38 %, respectively). The VEGF positive expression rates were also significantly higher in primary versus metastatic cancer (82 vs. 38 %, respectively; p < 0.001). By contrast, positive rates of HER-2 and COX-2 were not significantly different between different types of cancer. COX-2 correlated with HER-2 expression in both primary and relapsed/metastatic focuses of breast cancer. COX-2 also correlated with VEGF expression in primary breast cancer. Expressions of ER, PR, HER2, and COX-2 did not correlate between primary and relapsed/metastatic breast cancers, indicating that the treatment decision should be made according to the status of these markers in relapsed/metastatic focuses. The total change rates of ER, PR, HER-2, COX-2, and VEGF were 26, 18, 10, 30, and 58 %, respectively. In conclusion, HER-2 and COX-2, along with VEGF, appear to play a role in the development and progression of breast cancer. In addition, all of the studied markers may serve as indicators of prognosis.
在本研究中，我们评估了雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER-2）、环氧合酶-2（COX-2）和血管内皮生长因子（VEGF）在原发性及复发/转移性乳腺癌中的表达情况，以阐明这些标志物的临床意义。通过免疫组织化学法对50例原发性或转移性乳腺癌患者的标本进行了这些标志物的评估。原发性乳腺癌中ER的阳性率显著高于复发/转移性乳腺癌（分别为70%和38%，p = 0.002）。原发性癌与转移性癌中VEGF的阳性表达率也有显著差异（分别为82%和38%，p < 0.001）。相比之下，不同类型癌症之间HER-2和COX-2的阳性率无显著差异。在乳腺癌的原发性及复发/转移灶中，COX-2与HER-2表达相关。在原发性乳腺癌中，COX-2也与VEGF表达相关。原发性和复发/转移性乳腺癌中ER、PR、HER2和COX-2的表达不相关，这表明应根据复发/转移灶中这些标志物的状态来做出治疗决策。ER、PR、HER-2、COX-2和VEGF的总体变化率分别为26%、18%、10%、30%和58%。总之，HER-2、COX-2以及VEGF似乎在乳腺癌的发生和发展中发挥作用。此外，所有研究的标志物都可作为预后指标。
